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Dental and periodontal tissue development is a complex process involving various
cell-types. A finely orchestrated network of communications between these cells
is implicated. During early development, communications between cells from the
oral epithelium and the underlying mesenchyme govern the dental morphogenesis
with successive bud, cap and bell stages. Later, interactions between epithelial and
mesenchymal cells occur during dental root elongation. Root elongation and tooth
eruption require resorption of surrounding alveolar bone to occur. For years, it was
postulated that signaling molecules secreted by dental and periodontal cells control
bone resorbing osteoclast precursor recruitment and differentiation. Reverse signaling
originating from bone cells (osteoclasts and osteoblasts) toward dental cells was not
suspected. Dental defects reported in osteopetrosis were associated with mechanical
stress secondary to defective bone resorption. In the last decade, consequences of
bone resorption over-activation on dental and periodontal tissue formation have been
analyzed with transgenic animals (RANKTg and Opg−/− mice). Results suggest the
existence of signals originating from osteoclasts toward dental and periodontal cells.
Meanwhile, experiments consisting in transitory inhibition of bone resorption during root
elongation, achieved with bone resorption inhibitors having different mechanisms of
action (bisphosphonates and RANKL blocking antibodies), have evidenced dental and
periodontal defects that support the presence of signals originating bone cells toward
dental cells. The aim of the present manuscript is to present the data we have collected
in the last years that support the hypothesis of a role of bone resorption in dental and
periodontal development.
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INTRODUCTION
Early tooth development, more precisely initiation and morphogenesis, has been extensively
studied in the last decades. Factors implicated in the cross-talk between epithelial andmesenchymal
cells have been identified (for review Mitsiadis and Graf, 2009). Regarding later stages of tooth
development, more precisely dental and periodontal histogenesis, the differentiation processes
of mineralized tissue forming cells (namely amelogenesis, dentinogenesis and cementogenesis)
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have also been widely studied (Foster et al., 2007; Babajko et al.,
2014; Bleicher, 2014). Pathologies associated with dysfunctions of
these processes are nowadays well characterized as amelogenesis
imperfecta and dentinogenesis imperfecta (Cobourne and
Sharpe, 2013). Dental and periodontal histogenesis corresponds
to an important volumetric growth of these tissues, more
precisely regarding root formation. Consequently, the
surrounding alveolar bone has to be remodeled simultaneously
to enable normal tooth development and a dental functional
achievement through the eruption process.Bone remodeling
requires differentiation and activity of bone resorbing cells
from hematopoietic origin called osteoclasts. Osteoclastogenesis
is a well-characterized process with three consecutive steps
corresponding to precursors recruitment, their fusion into
mature polynucleated osteoclasts and finally the activation of
these mature osteoclasts (Lézot et al., 2010). The two major
signaling factors implicated in these differentiation steps are
presented in Figure 1.
Signals coming from dental and periodontal tissues were
shown to stimulate the alveolar bone remodeling (Wise,
2009). Indeed, these tissues secrete factors stimulating
osteoclastogenesis (Wise, 2009). The absence of alveolar
bone formation in the case of dental agenesis (Figure 2A)
supported the assertion that dental and periodontal tissues
are central coordinator elements in the development of the
dento-alveolar bone complex. Moreover, the apparently normal
development of the crown region observed in osteopetrotic
mouse models (Figure 2B), despite the altered bone resorption,
suggests that crown mineralized tissue formation is independent
of bone resorption.
In this context it was not surprising that potential reverse
signals from bone cells toward dental and periodontal tissues
FIGURE 1 | Schematic representation of different steps of osteoclastogenesis. The two mains factors controlling the differentiation called M-CSF and RANKL
are represented with their receptors. M-CSF is necessary to recruitment and expression of RANK at the surface of pre-osteoclasts. RANKL enable the fusion of
pre-osteoclasts in polykaryon and the final differentiation in mature osteoclasts. HSC, hematopoietic stem cell.
have been rarely considered. Recently, the analysis of dental
and periodontal development in mouse models of hyper-
resorption (RANKTg and Opg−/−) has changed the vision of
the dento-alveolar bone complex development (Castaneda et al.,
2011, 2013). Bone resorption was for the first time shown
to be an active element of the dental and periodontal tissues
development. This active implication was supported by results
of studies comprising transitory inhibition of bone resorption
during dental and periodontal tissue histogenesis, achieved with
bisphosphonate or RANKL blocking antibody (Lézot et al., 2014,
2015). In these studies dental and periodontal tissue defects
were associated and proportional to the induced delay of tooth
eruption.
Here we present a hypothetical model of tooth root and
periodontal development based on our own results as well as on
previously reported by other findings.
CURRENT STATUS CONCERNING TOOTH
ROOT AND PERIODONTAL FORMATION:
FACTS AND HYPOTHESES
Consequences of RANK Over-expression
in the Monocyte-macrophage Lineage
(RANKTg Mouse) on Dental and
Periodontal Development
In order to analyze the consequences of RANK over-expression
on dental and periodontal tissue growth, a transgenic mouse-
line overexpressing RANK in the osteoclast precursors (RANKTg ;
Duheron et al., 2011) was used. The dental and periodontal
phenotype of RANKTg mouse was analyzed comparatively to
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FIGURE 2 | Tooth agenesis consequence on alveolar bone formation (A) and close to normal crown morphology in osteopetrotic animals (B). Mandible
micro-radiographies and head frontal sections of newborn Msx1 and Dlx1/Dlx2 null mutants (A); Msx1 null mutant mouse image taken form Orestes-Cardoso et al.
(2002). Absence of alveolar bone formation in area of tooth agenesis (arrows). Micro-radiographies of wild type, C-Fos−/− and RANKl−/− 21 day-old mouse heads
(B) the formation of dental crowns (arrows) in osteopetrotic mutant mice with morphologies close to those of control littermate mice. M, molar; Tg, tongue.
littermate from birth to 1 month (Castaneda et al., 2011). Results
show a significant increase in the osteoclast number around the
tooth at all ages. This led to an earlier tooth eruption and an
accelerated tooth root elongation (Figure 3). The final root length
is not affected (Figure 4) but an important reduction of the root
diameter is observed no matter what the genetic background
(wild-type or Msx2 null mutant) considered (Castaneda et al.,
2011, 2013).
Interestingly, the complex phenotype of Msx2−/− mouse
combining amelogenesis imperfecta, root dysmorphia (defects
in Hertwig epithelial root sheaths (HERS) and epithelial
rests of Malassez), mild-osteopetrosis (with RANKl expression
severely decreased in the dental epithelium and alveolar
bone), and dentinogenesis imperfecta (Aïoub et al., 2007;
Molla et al., 2010; Berdal et al., 2011) was partly rescued
by RANK over-expression (Castaneda et al., 2013). Indeed,
RANK over-expression resulted in significant recovery of
all molar eruption and root elongation processes (Figure 4).
However, the roots remained shorter than in wild-type mice
and no improvement of the crown morphology was observed
(Figure 4).
These results show that root length is genetically determined
while root thickness is environmentally controlled, specifically by
the bone resorption ability.
The complete analysis of the RANKTg mouse dento-alveolar
bone complex phenotype has so enabled to demonstrate
that bone resorption is an important element of dental and
periodontal tissue development (Castaneda et al., 2011, 2013).
RANK over-expression induces an early tooth eruption and root
elongation with, as a final consequence, a reduction of the root
diameter. This accelerated tooth root elongation corresponds to
an increase of HERS cells and adjacent follicular sac mesenchyme
cells proliferation (Castaneda et al., 2011). The final root lengths
of the RANK transgenic and wild typemice are similar suggesting
that the interactions between epithelial andmesenchyme cells are
correct but accelerated (Castaneda et al., 2011). The Msx2−/−
mouse present many defects of the root formation (Aïoub et al.,
2007) including an important reduction of the length as shown in
Figure 5. The fact that, in the Msx2−/− mouse the RANK over-
activation has no repercussion on the final root length validates
that root length is genetically determined. Meanwhile, the root
diameter appears to be micro-environmentally controlled, more
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specifically by the bone resorption capability (Castaneda et al.,
2011, 2013). Finally the reverse relationship between bone
resorption level and the root diameter established by these studies
(Castaneda et al., 2011) could explain part of the root defects
seen in diseases with perturbations of the osteoclast function.
Concerning the root resorption observed in these diseases,
the question of a relationship between root thinness and the
prevalence of root resorption is raised. Interestingly, such thin
root resorptions are observed in the Opg−/− mouse (Koide et al.,
2013) in the context of a progressive loss of the alveolar bone.
FIGURE 3 | Accelerated root elongation in RANKTg mouse. Micro-CT
section in the mandible main axis show in 11 day-old RANKTg mouse a more
advanced root elongation (arrow) compared to wild type mouse.
In humans, RANK gene gains of function mutations have
been found in three seemingly distinctive disorders (the Familial
Expansile Osteolysis, the Expansile Skeletal Hyperphosphatasia
and the Early-onset Paget Disease of Bone). These mutations
increase the RANK signal peptide length and alter its normal
cleavage, what is believed to cause a NF-κB pathway over-
activation (Whyte and Hughes, 2002; Nakatsuka et al., 2003).
Such over-activation of the RANK-signaling pathway causes
a hyper-osteoclastic activity that increases the bone turnover.
A notable observation in these patients is an early tooth loss
associated in some case with an idiopathic external resorption
localized at either apical or cervical levels (Mitchell et al.,
1990; Hughes et al., 1994; Whyte, 2006). This convergence of
phenotype between human patients and RANKTg mice qualified
theRANKTg mouse as amodel of these three different pathologies
and confirmed the importance of bone resorption for dental and
periodontal tissue development.
Consequences of Transitory Inhibition of
Bone Resorption Using Zoledronic Acid or
a RANKL Blocking Antibody on Dental and
Periodontal Development
In order to analyze the consequences of transitory inhibitions
of bone resorption on dental and periodontal tissue growth, a
powerful pharmacologic inhibitor of bone resorption from the
bisphosphonate family was injected (four injections in total every
2 days) in newborn or 1 week-old mice. The impact on dental
and periodontal tissues was analyzed at the end of treatment,
1 and 3 months after the last injection. Zoledronic acid (ZOL),
a third generation bisphosphonate, was chosen for experiments
and C57BL/6J and CD1 mice used.
The different molars were not similarly affected by the
treatment. A relationship appears between severity of dental
and periodontal defects and each molar developmental period
FIGURE 4 | Roots and crown morphologies of the mandible first molars of adult wild-type, RANKTg, Msx2−/−,and Msx2−/− RANKTgmice. Roots of
RANKTg mouse molars are thinner and roots of Msx2−/− mouse molars are shorter as evidenced by dash lines. Crown of Msx2−/−−/− mouse are flat with no
cuspide independently of RANK over-expression.
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FIGURE 5 | Dental and periodontal consequences of four injections of ZOL or IKK22.5 in newborn mice, 3 months after the last injection. Head frontal
sections in the plane of the first molars show the presence of ankylosis (arrow), hyper-cementosis (stars), enamel organ disorganization (arrow-heads), and root
resorption (circle) in treated animals.
encompassed by the treatment. Indeed, when injections were
performed in newborn pups, the first molar was the most affected
and the third molar the least affected (Lézot et al., 2014, 2015).
The C57BL/6J mice appear to be more sensitive to ZOL than
the CD1 mice who need more elevated doses to obtain similar
effects (Lézot et al., 2015). In addition to delayed eruption,
the main observed defects of dental and periodontal tissues
were abnormal amelogenesis with disorganized ameloblasts,
root ankylosis, hypercementosis and with time presence
of root resorption (Figure 5; Lézot et al., 2014). These
results evidence that transitory inhibition of bone resorption
with ZOL irreversibly impact the histogenesis of dental and
periodontal tissues with long-term consequences that remain to
be evaluated.
Similar experiments were performed with another powerful
inhibitor of bone resorption, a RANKL blocking antibody named
IKK22.5.
Experimental results evidenced that while C57BL/6J mice
had several teeth included, CD1 mouse had only the upper
first molars included confirming the difference of sensitivity
to bone resorption inhibitors between these two mouse strains
(Lézot et al., 2015). Regarding the dental and periodontal
phenotype of non-includedmolars of CD1mouse, similar defects
to those induced by ZOL injections were observed (Figure 5).
Interestingly, after the end of treatment with the IK22.5 antibody,
a shorter period is necessary to observe neo-osteoclasts presence
on the alveolar bone surface than observed after ZOL treatment
(Lézot et al., 2015) signaling a more stable inhibition with ZOL
than with IKK22.5.
These results demonstrate that transitory use of two
different pharmacological bone resorption inhibitors during root
elongation induces dental and periodontal defects. This supports
our hypothesis of the existence of signaling from bone cells
toward dental cells. These powerful pharmacological inhibitors
were developed for the treatment of pathologies characterized
by excessive bone resorption such as juvenile Paget’s disease,
osteoporosis, primary or metastatic bone tumors and familial
expansile osteolysis (Silverman, 2011; Zwolak and Dudek, 2013;
Tella and Gallagher, 2014). In pediatric patients, a RANKL-
blocking antibody (Denosumab) is currently under clinical
evaluation for osteogenesis imperfecta (phase 2 clinical trial
NCT01799798) and for Giant Cell Tumor of Bone (phase
2 clinical trial NCT00680992) with promising preliminary
reports in both cases (Semler et al., 2012; Chawla et al., 2013;
Karras et al., 2013; Demirsoy et al., 2014; Federman et al.,
2014). Bisphosphonates are currently used for the treatment
of osteogenesis imperfecta (Barros et al., 2012; Bishop et al.,
2013; Ward and Rauch, 2013; Sousa et al., 2014) and juvenile
Paget’s disease (Demir et al., 2000; Cundy et al., 2004; Polyzos
et al., 2010; Saki et al., 2013). In addition, they are under
evaluation for treatment of primary bone tumors (Goldsby
et al., 2013; phase 3 Clinical trials NCT00987636, NCT00742924,
and NCT004470223) and Fibrous Dysplasia of Bone (phase 2
clinical trial NCT00445575). Concerning all these young patients,
dental and periodontal tissue developmental defects may occur
as a consequence of the bone resorption inhibition. Preclinical
studies and clinical observations have already demonstrated that
bisphosphonates, in particular alendronate and ZOL, delay or
inhibit tooth eruption causing several dental abnormalities (Grier
andWise, 1998; Bradaschia-Correa et al., 2007; Kamoun-Goldrat
et al., 2008; Hiraga et al., 2010) and may, as in the juvenile Paget’s
disease of bone, exert an inhibitory effect on bone mineralization
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(Polyzos et al., 2011). Such inhibition of mineralization has
been observed for various bisphosphonate in in vitro tests using
calvaria osteoblast culture (Widler et al., 2002).
CONCLUSION
The data presented in this review are unambiguous concerning
the role of bone resorption on the development of dental and
periodontal tissues and supports the hypothesis of a direct
implication of osteoclasts in dental and periodontal tissue
formation. Further studies will be necessary to decipher, at the
molecular level, signals originating from bone cells (presumably
osteoclasts) toward dental and periodontal cells. These signals
could be directly secreted by bone cells or released from the bone
matrix during the resorption.
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